Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04815096 · ClinicalTrials.gov registry record · Phase 2
Imaging Immune Activation in COVID-19
A Phase 2 study of Covid19 and SARS-CoV Infection, sponsored by CellSight Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04815096 is a Phase 2 study of Covid19 and SARS-CoV Infection that is actively recruiting participants, run by CellSight Technologies. The registered enrollment target is 80 participants, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04815096, a Phase 2 study of Covid19 and SARS-CoV Infection, is actively recruiting participants, sponsored by CellSight Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.
Conditions Studied
Interventions
- DRUG [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04815096
The ClinicalTrials.gov registry entry for NCT04815096 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (97% lower). The listed sponsor is CellSight Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) is the first listed.
NCT04815096 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04815096 about?
NCT04815096 is a clinical study titled "Imaging Immune Activation in COVID-19". This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual peri...
What is the current status of trial NCT04815096?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-04-15. Estimated completion is 2025-10-01.
What conditions does trial NCT04815096 study?
This clinical trial studies the following conditions: Covid19, SARS-CoV Infection.
What interventions are being tested in trial NCT04815096?
The interventions under investigation include: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) (DRUG).
Who is sponsoring clinical trial NCT04815096?
This trial is sponsored by CellSight Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04815096 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
Defibrotide for the Treatment of Severe COVID-19
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
ACTIVE NOT RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.